Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

Overview

This trial is active, not recruiting.

Condition

neuroblastoma

Sponsor

National Taiwan University Hospital

Start date

June 2007

End date

December 2014

Trial size

160 participants

Trial identifier

NCT01943097, 200703053M

Summary

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC)
activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by
(18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and
(123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and
follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and
clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors.

METHODS:

Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at
initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of
(18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET,
using tumor histology as the standard.